

REMARKS

Claims 1-17 are pending in this application. No claims have been canceled or added. Claims 1, 9, 16 and 17 have been amended to particularly and distinctly recite the claimed invention. No new subject matter has been added by the claim amendments. As such, Applicants respectfully request that the above claim amendments be entered and that the claims be allowed.

Applicants also submit the above amendments to the title of the invention. Please note that the amendments to the title are consistent with the previous amendments to the claims.


Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact Kecia Reynolds (Reg. No. 47,021) at the telephone number of the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.


Attached hereto is a marked-up version of the changes made to the application by this Amendment.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Marc S. Weiner, #32,181


MSW/KJR/jao
1060-0136P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment: Version with Markings to Show Changes Made

(Rev. 02/20/02)

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE TITLE


The title is amended as follows:

1,3-DIOXOLO[4,5-H][2,3][4,5-H//2,3]BENZODIAZEPINE

DERIVATIVES AS AMPA/KAINATE RECEPTOR INHIBITORS

IN THE CLAIMS

1. (Thrice Amended) A 1,3-dioxolo-[4,5-h][2,3]benzodiazepine compound of the formula I



wherein

A represents a hydrogen atom,

B means a hydrogen atom,

R¹ stands for a group of the formula

-(CH₂)_n-CO-(CH₂)_m-R, wherein

R represents a halo atom, a pyridyl group or a group of the formula -NR³R⁴, wherein

R^3 and R^4 mean, independently, a hydrogen atom, a C_{3-6} cycloalkyl group, a C_{1-4} alkoxy group, an amino group, a phenyl group optionally substituted by one or two C_{1-4} alkyl group(s), a C_{1-4} alkyl group which latter is optionally substituted by a phenyl group or a saturated heterocyclic group having 5 or 6 members and comprising 1 to 3 nitrogen atom(s) or a nitrogen atom and an oxygen atom as the heteroatom, and said heterocyclic group is optionally substituted by a phenyl group which latter is optionally substituted by 1 to 3 substituent(s), wherein the substituent [consists of] is a C_{1-4} alkoxy group, or

R^3 and R^4 form, with the adjacent nitrogen atom and optionally with a further nitrogen atom or an oxygen atom, a saturated or unsaturated heterocyclic group having 5 or 6 members, being optionally substituted by a phenyl group that is optionally substituted by 1 to 3 substituents, wherein the substituent is a C_{1-4} alkoxy group,

n has a value of 0, 1 or 2,

m has a value of 0, 1 or 2, or

A forms together with B a valence bond between the carbon atoms in positions 8 and 9, and in this case

R¹ represents a group of the formula

-CO-(CH₂)_p-R⁶, wherein

R⁶ stands for a halo atom, a phenoxy group, a C₁₋₄ alkoxy group or a group of the formula -NR⁷R⁸, wherein

R⁷ and R⁸ mean, independently, a hydrogen atom, a guanyl group, a C₃₋₆ cycloalkyl group or a C₁₋₄ alkyl group which latter is optionally substituted by a phenyl group or a saturated heterocyclic group having 5 or 6 members and comprising one or more nitrogen atom(s) or a nitrogen and an oxygen atom as the heteroatom, wherein the phenyl group is optionally substituted by 1 to 3 identical or different substituent(s), wherein the substituent is a C₁₋₄ alkoxy group, or

R⁷ and R⁸ form together with the adjacent nitrogen atom, an oxopyrrolidinyl group, a phthalimido group, or a saturated heterocyclic group having 5 or 6 members and comprising one or more nitrogen atom(s) or a nitrogen and an oxygen atom as the heteroatom, and said

heterocyclic group is optionally substituted by 1 to 3 identical or different substituent(s) selected from the group consisting of a hydroxy group, a phenyl group, a phenoxy group, a phenyl(C₁₋₄ alkyl) group or a phenoxy(C₁₋₄ alkyl) group, wherein in case of the substituents listed the phenyl or phenoxy group is optionally substituted by 1 to 3 identical or different substituent(s), wherein the substituent is a halo atom or a C₁₋₄ alkoxy group, and, in case of the phenoxy(C₁₋₄ alkyl) group, the alkyl group is optionally substituted by 1 or 2 hydroxy group(s),

p has a value of 0, 1 or 2,


R² stands for a nitro group, an amino group or a (C₁₋₄ alkanoyl)amino group, with the proviso that

- 1) if A forms together with B a valence bond, R² stands for a nitro group or an amino group and p has a value of 0, then R⁶ is different from a C₁₋₄ alkoxy group,
- 2) if A forms together with B a valence bond, R² stands for a nitro group or an amino group, p has a value of 0 or 1, and R⁶ represents a group of the formula -NR⁷R⁸, then one of R⁷ and

R^8 is different from a hydrogen atom or a C_{1-4} alkyl group,

- 3) if each of A and B stands for a hydrogen atom, n and m have a value of 0, then one of R^3 and R^4 represents a hydrogen atom, and the other of R^3 and R^4 is different from a hydrogen atom, a phenyl group or a C_{1-4} alkyl group, and
 - 4) if each of A and B stands for a hydrogen atom, n has a value of 0, m has a value of 1 or 2, and one of R^3 and R^4 stands for a hydrogen atom or a C_{1-14} alkyl group, then the other of R^3 and R^4 is different from a hydrogen atom or a C_{1-4} alkyl group,
 - 5) R is other than a chlorine atom; and with the further proviso that
 - 6) R^3 and R^4 cannot form with the adjacent nitrogen atom a pyrrolidine group,
- and pharmaceutically suitable acid addition salts thereof.

9. (Twice Amended) A pharmaceutical composition comprising a 1,3-dioxolo-[4,5-h][2,3]benzodiazepine compound of the formula I



wherein

A represents a hydrogen atom,

B means a hydrogen atom,

R¹ stands for a group of the formula

$-(CH_2)_n-CO-(CH_2)_m-R$, wherein

R represents a halo atom, a pyridyl group or a group of the formula $-NR^3R^4$, wherein

R³ and R⁴ mean, independently, a hydrogen atom, a C₃₋₆ cycloalkyl group, a C₁₋₄ alkoxy group, an amino group, a phenyl group optionally substituted by one or two C₁₋₄ alkyl group(s), a C₁₋₄ alkyl group which is optionally substituted by a phenyl group or a saturated heterocyclic group having 5 or 6 members and comprising 1 to 3 nitrogen atom(s) or a nitrogen atom and an oxygen atom as the heteroatom, and said heterocyclic group is optionally substituted by a phenyl group which is

optionally substituted by 1 to 3 substituent(s),
wherein the substituent [consists of] is a C₁₋₄
alkoxy group, or

R³ and R⁴ form, with the adjacent nitrogen atom and
optionally with a further nitrogen atom or an
oxygen atom, a saturated or unsaturated
heterocyclic group having 5 or 6 members, being
optionally substituted by a phenyl group that is
optionally substituted by 1 to 3 substituents,
wherein the substituent is a C₁₋₄ alkoxy group,

n has a value of 0, 1 or 2,

m has a value of 0, 1 or 2, or

A forms together with B a valence bond between the
carbon atoms in positions 8 and 9, and in this case
R¹ represents a group of the formula

-CO-(CH₂)_p-R⁶, wherein

R⁶ stands for a halo atom, a phenoxy group, a C₁₋₄
alkoxy group or a group of the formula -NR⁷R⁸,
wherein

R⁷ and R⁸ mean, independently, a hydrogen atom, a
guanyl group, a C₃₋₆ cycloalkyl group or a C₁₋₄
alkyl group which latter is optionally
substituted by a phenyl group or a saturated
heterocyclic group having 5 or 6 members and

comprising one or more nitrogen atom(s) or a nitrogen and an oxygen atom as the heteroatom, wherein the phenyl group is optionally substituted by 1 to 3 identical or different substituent(s), wherein the substituent is a C₁₋₄ alkoxy group, or

R⁷ and R⁸ form together with the adjacent nitrogen atom, an oxopyrrolidinyl group, a phthalimido group which is optionally substituted, or a saturated heterocyclic group having 5 or 6 members and comprising one or more nitrogen atom(s) or a nitrogen and an oxygen atom as the heteroatom, and said heterocyclic group is optionally substituted by 1 to 3 identical or different substituent(s) selected from the group consisting of a hydroxy group, a phenyl group, a phenoxy group, a phenyl(C₁₋₄ alkyl) group or a phenoxy(C₁₋₄ alkyl) group, wherein in case of the substituents listed the phenyl or phenoxy group is optionally substituted by 1 to 3 identical or different substituent(s), wherein the substituent is a halo atom or a C₁₋₄ alkoxy group, and, in case of the phenoxy(C₁₋₄ alkyl) group, the alkyl group is

optionally substituted by 1 or 2 hydroxy group(s),

p has a value of 0, 1 or 2,


R² stands for a nitro group, an amino group or a (C₁₋₄ alkanoyl)amino group, with the proviso that

- 1) if A forms together with B a valence bond, R² stands for a nitro group or an amino group and p has a value of 0, then R⁶ is different from a C₁₋₄ alkoxy group,
- 2) if A forms together with B a valence bond, R² stands for a nitro group or an amino group, p has a value of 0 or 1, and R⁶ represents a group of the formula -NR⁷R⁸, then one of R⁷ and R⁸ is different from a hydrogen atom or a C₁₋₄ alkyl group,
- 3) if each of A and B stands for a hydrogen atom, n and m have a value of 0, then one of R³ and R⁴ represents a hydrogen atom, and the other of R³ and R⁴ is different from a hydrogen atom, a phenyl group or a C₁₋₄ alkyl group,
- 4) if each of A and B stands for a hydrogen atom, n has a value of 0, m has a value of 1 or 2, and one of R³ and R⁴ stands for a

hydrogen atom or a C₁₋₄ alkyl group, then the other of R³ and R⁴ is different from a hydrogen atom or a C₁₋₁₄ alkyl group, and

5) R³ and R⁴ cannot form with the adjacent nitrogen atom a pyrrolidine group, or a pharmaceutically suitable acid addition salt thereof as the active ingredient and one or more conventional carrier(s).

16. (Thrice Amended) A method of treatment in which a patient suffering from epilepsy or being in a state after stroke is treated with a non-toxic dose of a 1,3-dioxolo-[4,5-h][2,3]benzodiazepine compound of the formula I,



wherein

- A represents a hydrogen atom,
- B means a hydrogen atom,
- R¹ stands for a group of the formula

$-(CH_2)_n-CO-(CH_2)_m-R$, wherein

R represents a halo atom, a pyridyl group or a group of the formula $-NR^3R^4$, wherein

R^3 and R^4 mean, independently, a hydrogen atom, a C_{3-6} cycloalkyl group, a C_{1-4} alkoxy group, an amino group, a phenyl group optionally substituted by one or two C_{1-4} alkyl group(s), a C_{1-4} alkyl group which latter is optionally substituted by a phenyl group or a saturated heterocyclic group having 5 or 6 members and comprising 1 to 3 nitrogen atom(s) or a nitrogen atom and an oxygen atom as the heteroatom, and said heterocyclic group is optionally substituted by a phenyl group which latter is optionally substituted by 1 to 3 substituent(s), wherein the substituent [consists of] is a C_{1-4} alkoxy group, or

R^3 and R^4 form, with the adjacent nitrogen atom and optionally with a further nitrogen atom or an oxygen atom, a saturated or unsaturated heterocyclic group having 5 or 6 members, being optionally substituted by a phenyl group that is optionally substituted by 1 to 3 substituents, wherein the substituent is a C_{1-4} alkoxy group,

n has a value of 0, 1 or 2,

m has a value of 0, 1 or 2, or

A forms together with B a valence bond between the carbon atoms in positions 8 and 9, and in this case

R¹ represents a group of the formula

-CO-(CH₂)_p-R⁶, wherein

R⁶ stands for a halo atom, a phenoxy group, a C₁₋₄ alkoxy group or a group of the formula -NR⁷R⁸, wherein

R⁷ and R⁸ mean, independently, a hydrogen atom, a guanyl group, a C₃₋₆ cycloalkyl group or a C₁₋₄ alkyl group which latter is optionally substituted by a phenyl group or a saturated heterocyclic group having 5 or 6 members and comprising one or more nitrogen atom(s) or a nitrogen and an oxygen atom as the heteroatom, wherein the phenyl group is optionally substituted by 1 to 3 identical or different substituent(s), wherein the substituent is a C₁₋₄ alkoxy group, or

R⁷ and R⁸ form together with the adjacent nitrogen atom, an oxopyrrolidinyl group, a phthalimido group, or a saturated heterocyclic group having 5 or 6 members and comprising one or

more nitrogen atom(s) or a nitrogen and an oxygen atom as the heteroatom, and said heterocyclic group is optionally substituted by 1 to 3 identical or different substituent(s) selected from the group consisting of a hydroxy group, a phenyl group, a phenoxy group, a phenyl(C₁₋₄ alkyl) group or a phenoxy(C₁₋₄ alkyl) group, wherein in case of the substituents listed the phenyl or phenoxy group is optionally substituted by 1 to 3 identical or different substituent(s), wherein the substituent is a halo atom or a C₁₋₄ alkoxy group, and, in case of the phenoxy(C₁₋₄ alkyl) group, the alkyl group is optionally substituted by 1 or 2 hydroxy group(s),


p has a value of 0, 1 or 2,

R² stands for a nitro group, an amino group or a (C₁₋₄ alkanoyl)amino group, with the proviso that

- 1) if A forms together with B a valence bond, R² stands for a nitro group or an amino group and p has a value of 0, then R⁶ is different from a C₁₋₄ alkoxy group,

- 2) if A forms together with B a valence bond, R^2 stands for a nitro group or an amino group, p has a value of 0 or 1, and R^6 represents a group of the formula $-NR^7R^8$, then one of R^7 and R^8 is different from a hydrogen atom or a C_{1-4} alkyl group,
 - 3) if each of A and B stands for a hydrogen atom, n and m have a value of 0, then one of R^3 and R^4 represents a hydrogen atom, and the other of R^3 and R^4 is different from a hydrogen atom, a phenyl group or a C_{1-14} alkyl group,
 - 4) if each of A and B stands for a hydrogen atom, n has a value of 0, m has a value of 1 or 2, and one of R^3 and R^4 stands for a hydrogen atom or a C_{1-14} alkyl group, then the other of R^3 and R^4 is different from a hydrogen atom or a C_{1-4} alkyl group,
 - 5) R^3 and R^4 cannot form with the adjacent nitrogen atom a pyrrolidine group, and
 - 6) R is other than a chlorine atom;
- or a pharmaceutically suitable acid addition salt thereof.

17. (Thrice Amended) A process for preparing a pharmaceutical composition suitable for the treatment of epilepsy or a state after stroke, characterized in that a 1,3-dioxolo-[4,5-h][2,3]benzodiazepine compound of the formula I,



wherein

A represents a hydrogen atom,

B means a hydrogen atom,

R¹ stands for a group of the formula

$-(CH_2)_n-CO-(CH_2)_m-R$, wherein

R represents a halo atom, a pyridyl group or a group of the formula $-NR^3R^4$, wherein

R³ and R⁴ mean, independently, a hydrogen atom, a C₃₋₆ cycloalkyl group, a C₁₋₄ alkoxy group, an amino group, a phenyl group optionally substituted by one or two C₁₋₄ alkyl group(s), a C₁₋₄ alkyl group which latter is optionally substituted by a phenyl group or a saturated

heterocyclic group having 5 or 6 members and comprising 1 to 3 nitrogen atom(s) or a nitrogen atom and an oxygen atom as the heteroatom, and said heterocyclic group is optionally substituted by a phenyl group which latter is optionally substituted by 1 to 3 substituent(s), wherein the substituent [consists of] is a C₁₋₄ alkoxy group, or

R³ and R⁴ form, with the adjacent nitrogen atom and optionally with a further nitrogen atom or an oxygen atom, a saturated or unsaturated heterocyclic group having 5 or 6 members, being optionally substituted by a phenyl group that is optionally substituted by 1 to 3 substituents, wherein the substituent is a C₁₋₄ alkoxy group,

n has a value of 0, 1 or 2,

m has a value of 0, 1 or 2, or

A forms together with B a valence bond between the carbon atoms in positions 8 and 9, and in this case R¹ represents a group of the formula

-CO-(CH₂)_p-R⁶, wherein

R⁶ stands for a halo atom, a phenoxy group, a C₁₋₄ alkoxy group or a group of the formula -NR⁷R⁸, wherein

R⁷ and R⁸ mean, independently, a hydrogen atom, a guanyl group, a C₃₋₆ cycloalkyl group or a C₁₋₄ alkyl group which latter is optionally substituted by a phenyl group or a saturated heterocyclic group having 5 or 6 members and comprising one or more nitrogen atom(s) or a nitrogen and an oxygen atom as the heteroatom, wherein the phenyl group is optionally substituted by 1 to 3 identical or different substituent(s), wherein the substituent is a C₁₋₄ alkoxy group, or

R⁷ and R⁸ form together with the adjacent nitrogen atom, an oxopyrrolidinyl group, a phthalimido group, or a saturated heterocyclic group having 5 or 6 members and comprising one or more nitrogen atom(s) or a nitrogen and an oxygen atom as the heteroatom, and said heterocyclic group is optionally substituted by 1 to 3 identical or different substituent(s) selected from the group consisting of a hydroxy group, a phenyl group, a phenoxy group, a phenyl(C₁₋₄ alkyl) group or a phenoxy(C₁₋₄ alkyl) group, wherein in case of the substituents listed the phenyl or phenoxy

group is optionally substituted by 1 to 3 identical or different substituent(s), wherein the substituent is a halo atom or a C₁₋₄ alkoxy group, and, in case of the phenoxy(C₁₋₄ alkyl) group, the alkyl group is optionally substituted by 1 or 2 hydroxy group(s),

p has a value of 0, 1 or 2,

R² stands for a nitro group, an amino group or a (C₁₋₄ alkanoyl)amino group, with the proviso that

- 1) if A forms together with B a valence bond, R² stands for a nitro group or an amino group and p has a value of 0, then R⁶ is different from a C₁₋₄ alkoxy group,
- 2) if A forms together with B a valence bond, R² stands for a nitro group or an amino group, p has a value of 0 or 1, and R⁶ represents a group of the formula -NR⁷R⁸, then one of R⁷ and R⁸ is different from a hydrogen atom or a C₁₋₄ alkyl group,
- 3) if each of A and B stands for a hydrogen atom, n and m have a value of 0, then one of R³ and R⁴ represents a hydrogen atom, and the other of

R^3 and R^4 is different from a hydrogen atom, a phenyl group or a C_{1-14} alkyl group,

- 4) if each of A and B stands for a hydrogen atom, n has a value of 0, m has a value of 1 or 2, and one of R^3 and R^4 stands for a hydrogen atom or a C_{1-4} alkyl group, then the other of R^3 and R^4 is different from a hydrogen atom or a C_{1-4} alkyl group,

- 5) R is other than a chlorine atom; and with the further proviso that

- 6) R^3 and R^4 cannot form with the adjacent nitrogen atom a pyrrolidine group,

or a pharmaceutically suitable acid addition salt thereof, together with one or more conventional carrier(s), is converted to a pharmaceutical composition.